GILEAD award

The Belgian Hematology Society (BHS), with the support of an unrestricted grant from Gilead Sciences and Kite, a Gilead company, has the pleasure to announce two grants to support research in the field of cellular therapies in hematological disease.


Researchers working in hematology are invited to submit their project and apply for the Gilead Cell Therapy Grants. All information on rules and regulations are available on the homepage , as is the application form. 

The deadline for submission is December 1st, 2020, midnight.

The jury will select two winning projects based on their innovative character, which will be awarded with EUR 25.000. The award ceremony will take place at the 36th BHS general annual meeting, January 30, 2021.

We are looking forward to receiving outstanding projects that can advance the outcomes of hematological diseases through cellular therapies.


Ann Janssens, President of the BHS


Who can apply?

Which projects are eligible?

Application requirements?

Projects can be submitted online via below button 


Only submission through the online tool is possible. Submissions sent by e-mail will not be considered.

Candidates working at a pharmaceutical company are excluded.


A monetary grant of EUR 25.000 will be awarded to the winner. The results of the selection will be announced during the 2021 General Annual Meeting of the BHS.   This award has been made possible with an unrestricted grant from Gilead Sciences Belgium.